Gentleman
TD Cowen updated Stoke Therapeutics (NASDAQ: STOCKS) to be purchased based on updated Phase 1/2 data for the company’s STK-001 epilepsy drug candidate.
“The update showed a significantly improved clinical profile compared to previous data cuts in July 2023 and adverse events ((December 2023)) which gives us confidence that STK-001 could be the first disease-modifying therapy for Dravet syndrome,” the analysts wrote in their note.
TD Cowen said it is increasing the success probability for STK-001 in Dravet syndrome to 70% and expects market penetration of up to 40-60% in the Dravet refractory market, with peak sales of $355 million by 2036.
According to the Epilepsy Foundation, Dravet syndrome is a rare genetic form of epilepsy that does not respond well to antiseizure medications.